Show simple item record

FieldValueLanguage
dc.contributor.authorHamid, S.en
dc.contributor.authorAlvares Da Silva, M.R.en
dc.contributor.authorBurak, K.W.en
dc.contributor.authorChen, T.en
dc.contributor.authorDrenth, J.P.H.en
dc.contributor.authorEsmat, G.en
dc.contributor.authorGaspar, R.en
dc.contributor.authorLabrecque, D.en
dc.contributor.authorLee, A.en
dc.contributor.authorMacedo, G.en
dc.contributor.authorMcmahon, B.en
dc.contributor.authorNing, Q.en
dc.contributor.authorReau,N.en
dc.contributor.authorSonderup, M.en
dc.contributor.authorVan Leeuwen, D.J.en
dc.contributor.authorArmstrong, D.en
dc.contributor.authorYurdaydin, C.en
dc.date.accessioned2021-06-02T04:55:20Z
dc.date.available2021-06-02T04:55:20Z
dc.date.issued2021
dc.identifier.urihttps://hdl.handle.net/2123/25300
dc.description.abstractSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the least deadly but most infectious coronavirus strain transmitted from wild animals. It may affect many organ systems. Aim of the current guideline is to delineate the effects of SARS-CoV-2 on the liver. Asymptomatic aminotransferase elevations are common in coronavirus disease 2019 (COVID-19) disease. Its pathogenesis may be multifactorial. It may involve primary liver injury and indirect effects such as "bystander hepatitis," myositis, toxic liver injury, hypoxia, and preexisting liver disease. Higher aminotransferase elevations, lower albumin, and platelets have been reported in severe compared with mild COVID-19. Despite the dominance of respiratory disease, acute on chronic liver disease/acute hepatic decompensation have been reported in patients with COVID-19 and preexisting liver disease, in particular cirrhosis. Metabolic dysfunction-associated fatty liver disease (MAFLD) has a higher risk of respiratory disease progression than those without MAFLD. Alcohol-associated liver disease may be severely affected by COVID-19 - such patients frequently have comorbidities including metabolic syndrome and smoking-induced chronic lung disease. World Gastroenterology Organization (WGO) recommends that interventional procedures such as endoscopy and endoscopic retrograde cholangiopancreatography should be performed in emergency cases or when they are considered strictly necessary such as high risk varices or cholangitis. Hepatocellular cancer surveillance may be postponed by 2 to 3 months. A short delay in treatment initiation and non-surgical approaches should be considered. Liver transplantation should be restricted to patients with high MELD scores, acute liver failure and hepatocellular cancer within Milan criteria. Donors and recipients should be tested for SARS-CoV-2 and if found positive donors should be excluded and liver transplantation postponed until recovery from infection.en
dc.language.isoenen
dc.rightsOther
dc.subjectCOVID-19en
dc.subjectCoronavirusen
dc.titleWGO Guidance for the Care of Patients with COVID-19 and Liver Diseaseen
dc.typeArticleen
dc.identifier.doi10.1097/MCG.0000000000001459
usyd.facultySeS faculties schools::Faculty of Medicine and Healthen


Show simple item record

Associated file/s

There are no files associated with this item.

Associated collections

Show simple item record

There are no previous versions of the item available.